Formulation & Delivery Series UK

Upperton will be exhibiting at the Formulation & Delivery Series UK: VIRTUAL from Wednesday 8th to Thursday 9th July (UTC+1). 

We are looking forward to meeting both new and existing clients on our stand. So if you have an API which requires formulation development or clinical manufacture, please contact us to book an appointment or alternatively drop by our exhibition stand to talk to Upperton’s team

Showcase Presentation, Thursday 9th July at 10.30 am

Upperton’s Founder & CEO, Richard Johnson will be presenting ‘Upperton Pharma Solutions: A Specialist CDMO’ on Thursday 9th July 10.30 am at the Formulation & Delivery Series UK: Virtual conference.

This talk will cover: 

  • History and recent growth
  • Full scope of services
  • What to expect when working with Upperton

Round-table Discussion, Thursday 9th July at 11.30 am

Upperton’s Technical Consultant will be hosting the round-table discussion ‘CDMO – Oral Drug Delivery Challenges During Early
Development’ on Thursday 9th July 11.30 am at the Formulation & Delivery Series UK: Virtual conference.

This round-table discussion will cover:

  • What currently are the most common drug delivery challenges seen in the CDMO industry
  • Oral bioavailability is obviously a big challenge what are key issues when selecting a suitable enabling technology
  • Is there ever a case for by-passing formulation development and simply preparing a simple powder in capsule formulation for the first in human studies

Upperton Team

Richard Johnson
Founder and CEO

Dr Richard Johnson founded Upperton Pharma Solutions in August 1999, and continues to play a key role in the management and strategic development of the company. With over 30 years of experience in the pharmaceutical, biotechnology and drug delivery fields, Richard previously held senior management positions at Andaris Limited (Vectura) and Delta Biotechnology (now Albumedix). Richard holds an honours degree in Biology from University of York and a Ph.D. from the University of Warwick and has a proven track record in successfully developing innovative pharmaceutical products from early feasibility studies through to commercial products.

Laura Mason
Director of Business Operations

Dr Laura Mason joined Upperton in 2016 as a Project Scientist, quickly progressing to the role of Business Operations Director. Laura has previous experience within solid oral dosage form development having completed her PhD in the School of Pharmacy at the University of Nottingham, and her Pharmacy Pre-Registration Year at Merck Sharp and Dohme and Guy’s & St Thomas’ Hospital. Laura is a UK Registered Pharmacist, the current treasurer of the UKICRS and a member of several pharmaceutical societies. Laura supports the introduction and co-ordination of the company’s R&D projects.

Ian Lafferty
Technical Consultant

Dr Ian Lafferty has recently joined Upperton Pharma Solutions as a Technical Consultant. Ian has 25 years’ technical and operational experience in early phase pharmaceutical development encompassing the formulation design, development, process optimisation and manufacture of a wide range of dosage forms including oral solids, inhaled powders, suspensions and injectables with a focus on challenging molecules, enabling technologies and high potent handling. He also has significant experience in facility design and management.

Ian has held senior roles at several emerging and growing CDMOs providing strategic and operational leadership to ensure excellence in all aspects of providing pharmaceutical services.

Klara Fisken
Marketing & Communications Officer

Klara Fisken joined Upperton in August 2018, after completing a three month project at Upperton which was part of her MSc in Applied Biopharmaceutical Biotechnology and Entrepreneurship from the University of Nottingham. Klara is responsible for Upperton’s marketing which includes newsletters, creating marketing materials, press releases, website and social media. 

Recent News at Upperton

Upperton have been investing in new equipment to enhance our capabilities in manufacturing final dosage forms. Our current focus is in enhancing / increasing out put in our tabletting capabilities. In 2019, Upperton acquired a new cutting edge tablet press, Futorque X by KG-Pharma which can produce up to 130,000 tablets per hour or supporting DoE and research studies with minimal material. 

The O Hara LC M5 coater was also purchased in 2019; film coating is a key process offering a wide range of drug delivery benefits including: taste/odour masking, stability protection, modification of release profiles, ease of administration and product identification. Upperton will follow these investments through the purchase of further tabletting equipment.

The new service UpperSolv was launched in late 2019. UpperSolv™ is a signposted pathway to rapid, tailored screening of small quantities of API, the manufacture of prototype formulations using a range of scalable enabling technologies and comparison of the biopharmaceutical performance via a PK assessment.

The Formulation & Delivery Series UK

The Formulation & Delivery Series UK, combines the 6th Annual Formulation & Drug Delivery Congress, 5th Annual Inhalation & Respiratory Drug Delivery Congress and Biomanufacturing Congress. With over 300 influencers, experts and researchers attending to learn about the latest updates in biopharmaceutical advancements shaping the future of drug product development.